Suppr超能文献

肺内注射重组活化凝血因子VII治疗复发性急性淋巴细胞白血病合并血小板输注无效所致的危及生命的肺出血

Intrapulmonary rFVIIa for life threatening pulmonary hemorrhage in a case of relapsing acute lymphoblastic leukemia and platelet refractoriness.

作者信息

Almomen Abdulkareem, Aleem Aamer, Alshaik Mashael, Hasanato Rana

机构信息

Center of Excellence in Thrombosis and Hemostasis, College of Medicine and King Khalid University Hospital, King Saud University , Riyadh , Saudi Arabia .

出版信息

Platelets. 2014;25(6):452-4. doi: 10.3109/09537104.2013.835797. Epub 2013 Oct 8.

Abstract

Platelet refractoriness may lead to life-threatening gastro-intestinal, intracranial or pulmonary hemorrhage that is difficult to control despite massive platelet and red cell transfusion, antifibrinolytic agents, high dose corticosteroids, immunoglobulin and intravenous (I.V.) recombinant activated factor VII (rFVIIa). In cases with pulmonary hemorrhage, intrapulmonary administration of rFVIIa may be more effective in non-responsive cases. We report a 51-year-old man with relapsing acute lymphoblastic leukemia (ALL) and platelet refractoriness, who suffered a life-threatening pulmonary hemorrhage that was refractory to massive platelet transfusion, tranexamic acid, high dose corticosteroids, immunoglobulin and intravenous rFVIIa, but responded immediately to a single intrapulmonary dose of rFVIIa that was inhaled with a jet nebulizer assistance through the endotracheal tube.

摘要

血小板输注无效可能导致危及生命的胃肠道、颅内或肺部出血,尽管大量输注血小板和红细胞、使用抗纤维蛋白溶解剂、高剂量皮质类固醇、免疫球蛋白和静脉注射重组活化因子VII(rFVIIa),但仍难以控制。在肺部出血的病例中,对于无反应的病例,肺内注射rFVIIa可能更有效。我们报告了一名51岁患有复发性急性淋巴细胞白血病(ALL)且存在血小板输注无效的男性患者,他发生了危及生命的肺部出血,对大量血小板输注、氨甲环酸、高剂量皮质类固醇、免疫球蛋白和静脉注射rFVIIa均无反应,但通过气管插管借助喷射雾化器吸入单次肺内剂量的rFVIIa后立即有了反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验